|
Synonyms: ALN-65492 | ALN-TTRSC02 | Amvuttra® | votrisiran
vutrisiran is an approved drug (EMA, FDA & UK MHRA (2022))
Compound class:
Nucleic acid
Comment: Vutrisiran (ALN-65492) is a GalNAc conjugated double-stranded small interfering ribonucleic acid (siRNA) drug. It acts as a transthyretin (TTR) synthesis inhibitor.
We have been unable to locate a full chemical SMILES for the drug, or its HELM notation. |
Classification  |
|
| Compound class | Nucleic acid |
| Compound subclass | siRNA |
| Target | transthyretin (TTR) mRNA |
| Approved drug? | Yes. FDA (2022) | EMA (2022) | UK MHRA (2022) |
| International Nonproprietary Names |
|
| INN number | INN |
| 10579 | vutrisiran |
| Synonyms |
| ALN-65492 | ALN-TTRSC02 | Amvuttra® | votrisiran |
| Database Links |
|
| CAS Registry No. | 1867157-35-4 (source: WHO INN record) |
| ChEMBL Ligand | CHEMBL4594511 |
| DrugBank Ligand | DB16699 |
| GtoPdb PubChem SID | 504705435 |
| Search PubMed clinical trials | vutrisiran |
| Search PubMed titles | vutrisiran |
| Search PubMed titles/abstracts | vutrisiran |
